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Abstract
Downregulation of the muscle-specific microRNA-1 (miR-1) mediates the induction of pathologic cardiac hypertrophy.
Dysfunction of the gap junction protein connexin 43 (Cx43), an established miR-1 target, during cardiac hypertrophy
leads to ventricular tachyarrhythmias (VT). However, it is still unknown whether miR-1 and Cx43 are interconnected
in the pro-arrhythmic context of hypertrophy. Thus, in this study we investigated whether a reduction in the extent of
cardiac hypertrophy could limit the pathological electrical remodeling of Cx43 and the onset of VT by modulating
miR-1 levels. Wistar male rats underwent mechanical constriction of the ascending aorta to induce pathologic left
ventricular hypertrophy (LVH) and afterwards were randomly assigned to receive 10mg/kg valsartan, VAL (LVH
+VAL) delivered in the drinking water or placebo (LVH) for 12 weeks. Sham surgery was performed for control
groups. Programmed ventricular stimulation reproducibly induced VT in LVH compared to LVH+VAL group. When
compared to sham controls, rats from LVH group showed a significant decrease of miR-1 and an increase of Cx43
expression and its ERK1/2-dependent phosphorylation, which displaces Cx43 from the gap junction. Interestingly,
VAL administration to rats with aortic banding significantly reduced cardiac hypertrophy and prevented miR-1 down-
regulation and Cx43 up-regulation and phosphorylation. Gain- and loss-of-function experiments in neonatal
cardiomyocytes (NCMs) in vitro confirmed that Cx43 is a direct target of miR-1. Accordingly, in vitro angiotensin II
stimulation reduced miR-1 levels and increased Cx43 expression and phosphorylation compared to un-stimulated
NCMs. Finally, in vivo miR-1 cardiac overexpression by an adenoviral vector intra-myocardial injection reduced Cx43
expression and phosphorylation in mice with isoproterenol-induced LVH. In conclusion, miR-1 regulates Cx43
expression and activity in hypertrophic cardiomyocytes in vitro and in vivo. Treatment of pressure overload-induced
myocyte hypertrophy reduces the risk of life-threatening VT by normalizing miR-1 expression levels with the
consequent stabilization of Cx43 expression and activity within the gap junction.
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Introduction
Although cardiac hypertrophy is a compensatory response to
overload conditions such as hypertension or valvular heart
diseases [1], it is considered an independent cardiovascular
risk factor [1,2]. Ventricular tachyarrhythmias (VT), including
ventricular fibrillation, are major determinants of sudden death
in patients with cardiac hypertrophy [3]. These arrhythmias, in
fact, are triggered by the presence of an arrhythmogenic
substrate that is typical of hearts with pathological hypertrophy
[4]. Several electrophysiological abnormalities have been
ascribed to cardiac hypertrophy, including increased duration of
action potential, reduced resting membrane potential and
delayed conduction velocity (due to interstitial fibrosis). The
latter results in depolarization and recovery of heterogeneous
areas with increased refractory period [5]. Signaling pathways
that promote deterioration of cardiac electrophysiological
performance are currently an area of intense research, since
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their inhibition through fine tuning of the action potential can be
considered a new therapeutic approach in arrhythmias [6].
The renin-angiotensin system is up-regulated in response to
the stress conditions imposed on the heart [7]. The effects of
angiotensin II (AngII) are mainly due to its interaction with the
AngII type 1 receptor (AT1R), which belongs to a superfamily
of receptors with seven transmembrane domain coupled to G-
proteins and whose direct inhibition has been postulated to
normalize the electrophysiological properties of
cardiomyocytes, probably through the stabilization of their
electrical plasmatic membrane. Accordingly, it has been
recently shown that AT1R activation could exert
arrhythmogenic effect through c-Src tyrosine kinase-mediated
connexin 43 (Cx43) displacement from the gap junctions [8].
Cx43 is the highest expressed protein in the myocardium
devoted to regulate intercellular connections in mammalian
hearts. In normally functioning cardiac ventricles Cx43 is
localized at the intercalated disks, where it supports
longitudinal and transverse spread of the action potential [9].
The contractile dysfunction and arrhythmias that occur during
hypertrophy depend, in addition to a metabolic imbalance,
mainly on excitability and electrical coupling. Phosphorylation
and dephosphorylation of Cx43 mediated by different protein
kinases, affect the processes of trafficking, assembly,
degradation, expression, and distribution hence altering the
number of functional channels, the so-called "open probability",
and conductance properties [10]. Nevertheless, it is not
completely understood how Cx43 dysregulation increases
arrhythmic risk.
Recent works from our and other laboratories have
characterized the role of several microRNAs (miRs) in
cardiovascular biology and diseases [11–13]. MiRs are a class
of small non-coding RNA molecules, about 22 nucleotides long,
which can base-pair sequences partially complementary to the
3'-UTR located in regions of mRNA targets, arresting the
process of translation [14]. Selected miRs’ dysregulation alters
the cellular responses of cardiomyocytes and non-
cardiomyocytes to specific signaling upon the pathological
hemodynamic overload, leading to cardiac hypertrophy and
heart failure [12]. Furthermore, miRs play an essential role in
controlling cardiac excitability since, by acting at post-
transcriptional level, such molecules regulate the expression of
gap-junctions and ion channels [15,16]. Among the highly
expressed miRs in the myocardium, miR-1 has an essential
regulatory role in the development of cardiac hypertrophy and it
controls cardiac electrophysiology for its ability to modulate the
expression levels of molecular targets that adjust the electrical
coupling of the cardiac fiber cells [17]. In particular, Cx43 is a
direct target of miR-1 gene-silencing activity [34,35]. However,
it is still unknown whether miR-1 and Cx43 are interconnected
in the pro-arrhythmic context of left ventricular hypertrophy
(LVH) and whether miR-1 expression and activity can be
regulated by an anti-hypertrophic treatment, such as AT1R
antagonization.
Therefore, the purpose of this study was to examine: (i)
whether miR-1 and Cx43 dysfunctions underlie the onset of VT
associated to cardiac hypertrophy in a rat model of pressure
overload; (ii) whether miR-1 directly modulates Cx43
expression and activity in hypertrophic myocytes in vitro and in
vivo; (iii) to assess whether the treatment of pathologic LVH by
AT1R blockade could normalize miR-1 levels, limit the adverse
electrical remodeling of Cx43 and reduce the induction of life-
threatening VT.
Materials and Methods
In vivo experimental protocols
Male Wistar rats (90-120g, 7 weeks of age, N=22) were used
for an aortic banding protocol conformed to Directive
2010/63/EU of the European Parliament and approved by the
Italian Ministry of Health and by Institutional Animal Care and
Use Committee of Magna Graecia University. Briefly, rats were
anesthetized as previously reported [18], and after confirmation
of pain reflex absence, were intubated and ventilated by
dedicated apparatus while placing a tantalum clip on the
ascending aorta through a left lateral mini-thoracotomy; in
further twenty rats a sham surgery was performed. After
allowing recovery, animals were randomized to receive either
placebo (LVH, n=12; SHAM, n=10) or valsartan at the dosage
of 10 mg/kg/day added to the drinking water (LVH+VAL, n=10;
SHAM+VAL, n=10) for 12 weeks.
In an additional set of experiments to assess the direct role
of miR-1 on Cx43 expression and activity, myocyte hypertrophy
was induced in 8-12 weeks old C57BL/6 mice by Isoproterenol
daily injection (Iso, 50mg/kg body weight i.p.) for 14 days [19].
Briefly, in a group of mice (n=7) an Adenoviral vector (1011
pfu/mL) carrying a miR-1 construct under the ubiquitous CMV
promoter (Ad-miR-1) [11] was intra-myocardially released by 5
direct epicardial injections of 3µL each in the anterior LV and
apical region, followed by delivering of 30µL of adenoviral
construct dissolved in 30% pluronic F127 gel (Sigma), in order
to cover the entire LV wall. An Adeno-Empty vector was
equally injected in additional mice (n=7). Levels of miR-1 are
significantly up-regulated in cardiac muscle already at 48-72
hours (data not shown). Thus, 72 hours later, 8 adenovirus-
transfected mice were administered Iso as above described
(n=4, Ad-Empty+Iso and n=4, Ad-miR-1+Iso) while 6 mice were
administered only saline solution (n=3 Ad-Empty+Saline and
n=3 Ad-miR-1+Saline). Mice were accordingly sacrificed 14
days later [19].
At the end of the study protocol, each rat or mouse was
sacrificed by lethal anaesthesia and morphometric parameters
were analyzed. Subsequently, LV was longitudinally cut in two
halves and one of the two was flash-frozen in liquid nitrogen
and stored at -80°C for molecular biology studies while the
other was fixed in 10% buffered formalin for
immunohistochemistry studies (see below).
Echocardiographic evaluation
Echocardiographic measurements were obtained in basal
conditions and after 12 weeks from banding. Briefly, under light
anesthesia, examinations were performed with a 7.5MHz
phased-array transducer (VIVID E, GE Healthcare, Fairfield,
CT, USA), as previously described [20]. Interventricular septum
and posterior wall thicknesses (IVSWth and PWth,
respectively), LV end-systolic (LVESD) and end-diastolic
microRNA-1 and Ventricular Tachyarrhythmias
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(LVEDD) diameters were measured with standard technique in
parasternal long and short axis. Finally, the fractional
shortening (FS) was calculated by two blinded observers.
Hemodynamic studies
A 2F conductance catheter (Millar Instruments Inc, Houston,
TX, USA) was inserted retrogradely through the right common
carotid artery into the LV 12 weeks after aortic banding.
Systolic blood pressure (SBP) and diastolic BP (DBP) were
recorded at level of the aortic arch, then catheter was
advanced through the clip for trans-stenotic supravalvular
gradient assessment (in banded rats), and finally heart rate
(HR), LV end diastolic pressure (LVEDP), LV maximal systolic
pressure (LVmax) and the maximal and minimal first derivative
of the LV pressure over time [LV(dP/dtmax) and LV(dP/dtmin),
respectively], were assessed at intracavitary level [21]. Data
were acquired on digital media at a sampling of 1,000Hz
(PowerLab System, ADInstruments Inc, Colorado Springs, CO,
USA) and all the parameters were analyzed offline [22] by a
dedicated software (LabChart, ADInstruments Inc, Colorado
Springs, CO, USA).
Electrophysiological study
Electrophysiological evaluation was performed at the end of
the study after hemodynamic assessments in rats of each
group. A stable 3-lead electrocardiographic digital tracing was
obtained by placing the leads in standard position not
interfering with other equipments [23] and a dedicated bipolar
catheter was advanced anterogradely into the right ventricle
through the external jugular vein. A standard intracavitary
stimulation protocol of twenty impulses at a cycle length of
100ms (S1), followed by 3 extrastimuli (S2, S3, and S4) at
shorter coupling intervals was delivered at 2V output energy
and 0.5ms pulse width by using an external apparatus
(MEDICO, Italy). Ventricular capture was assessed online while
the induced ventricular arrhythmias were offline analyzed using
LabChart7Pro software (ADInstruments Inc, Colorado Springs,
CO, USA).
Recording of intracavitary electrograms
Electrograms were recorded on a multichannel computerized
data acquisition system at a sampling rate of 1,000Hz. At this
sampling rate, temporal resolution was sufficient for measuring
rapid electrical deflections over short distances. The ventricular
effective refractory period (VERP), deﬁned as the longest
coupling interval of the premature stimulus that failed to
activate the entire heart, was determined at the time of
electrophysiological studies. Signals were band-pass filtered
(low cutoff, 0.16Hz; high cutoff, 1kHz) and digitized with 16bit
resolution and a sampling frequency of 1kHz. The selected
gain for balancing input noise of the system was 4µV (peak-
peak). Every twentieth stimulus was followed by 1 premature
stimulus. Starting at basal cycle length of 150ms, the coupling
interval of the premature stimulus was reduced in steps of 5ms
until VERP [24]. Monophasic action potential duration at 90%
repolarization (MAPD90) was evaluated at endocardial level.
Signals were amplified, band-pass filtered, and digitized by a
dual bioamplifier (ADInstruments) before extraction and
analysis. Recordings were accepted if they had a stable
baseline, a rapid upstroke phase with consistent amplitude, a
smooth repolarization phase, and a stable duration. MAPD90
was defined as the monophasic action potential interval from
the onset of zero-phase depolarization to the 90%
repolarization level. Basically, right ventricles were stimulated
as above indicated for VERP and activation was assessed as
previously described [24].
Tissue Harvesting, Histology, Immunohistochemistry
and Confocal Microscopy
After completion of the cardiac function measurements, the
isolated hearts were cut into right and left ventricles, and right
and left atria. After being weighed, the LV was sectioned into 2
parts, and one of the two was fixed in 10% formalin and
paraffin embedded, and 5µm cross sections were prepared on
a microtome (Leica). Mouse cardiomyocyte cross-sectional
area was obtained as previously described [19].
Immunohistochemistry and confocal microscopy were
performed as previously described [25,26]. Briefly, myocyte
cytoplasm was detected using an antibody against α-
sarcomeric actin (1:50 dilution; clone 5C5, Sigma), for 2hrs at
37°C and this was detected with anti-mouse IgM Texas Red
(1:100 dilution; Jackson Immunoresearch). Cx43 was detected
with a rabbit polyclonal antibody against Cx43 (1:50 dilution;
Abcam) overnight at 4°C. This antibody was detected with an
anti-rabbit IgG FITC (1:100 dilution; Jackson Immunoresearch).
Cx43 phosphorylated on Ser 279/282 was detected with a goat
polyclonal (1:50 dilution; Santa Cruz) antibody for 2hrs at 37°C
which was ligated by an anti-goat IgG FITC (1:100 dilution;
Jackson Immunoresearch). Nuclei were counterstained with
DAPI. Sections were mounted in Vectashield, analyzed and
scanned using confocal microscopy (Zeiss LSM 710).
Isolation and culture of neonatal rat ventricular
cardiomyocytes
Primary cultures of cardiomyocytes were obtained from both
ventricles of rats at 1-2 days of age. Isolated ventricles were
plated in D–PBS with heparin, minced and enzymatically
digested. Fragments were placed in a solution combining
trypsin (Gibco-Life Technologies Italia, MB, Italy) and DNAse I
(Sigma Aldrich, St. Louis, MO, USA) in MEM base and
subjected to several cycles of digestion at 37°C, then placed in
flasks pre-treated with laminin and resuspended in D-MEM with
10% FBS. After 48hrs the culture medium was replaced with
medium containing supplements and 3% FBS [27]. On the third
day cardiomyocytes were stimulated with 5µmol/L AngII or
AngII plus 10µmol/L VAL for 3hrs. Cells were then collected
and evaluated for immunoblotting analysis and Real Time RT-
PCR quantification.
Ca2+ transients
The intracellular Ca2+ transients were measured in basal
conditions and after AngII treatment alone or in combination
with VAL, as previously described [28]. Briefly, fluo-3 dye was
added to cultured cells after respective treatments directly into
DMEM (10µM for 15min), then fluorescence was assessed at
confocal laser microscopy imaging. Acquisitions were
microRNA-1 and Ventricular Tachyarrhythmias
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processed to obtain a peak value of F/F0, whereas F is the
peak of fluorescent level and F0 is the resting fluorescent level.
Determination of RNA levels by RT-PCR
Extracts of total RNA were obtained from both LV and
cultured cardiomyocytes of each group using mirVana miRNA
Isolation Kit (Ambion-Life Technologies Italia, MB, Italy)
according to the manufacturer’s protocol. Expression levels of
mature miRNAs [29] were analyzed by real-time RT-PCR using
TaqMan microRNA assays (Applied Biosystems, Foster City,
CA). In brief, 10ng of total RNA were reverse-transcribed with
specific stem-loop RT primers using TaqMan microRNA
reverse transcription kit, according to the manufacturer’s
instructions. Real-time RT-PCR was performed on cDNA using
specific primers designed on rat miR-1 sequence 5'-UGG AAU
GUA AAG AAG UGU GUA U-3'. The reactions were incubated
in a 96-well plate at 95°C for 10min, followed by 40 cycles at
95°C for 15s followed by 60°C for 60s. The U6 expression of
the housekeeping gene was used as endogenous control for
data normalization. Cx43 mRNA levels were assessed by
Taqman-gene expression assay [13].
Preparation of protein extracts and membrane
fractionation
Rat hearts were homogenized in a buffer consisting of Tris/
EDTA (Tris/HCl 50mM, EDTA 4mM, pH 7.4), Triton X-100 and
protease and phosphatase inhibitors. After homogenization,
lysates were kept on ice for 20min and then centrifuged at
2000 rpm for 5min at 4°C. Supernatant was then transferred to
high speed tubes and centrifuged again at 17.500 rpm for
25min at 4°C; finally, supernatant (cytosolic fraction) was
isolated and pellet (membrane fraction) was resuspended in
200µL buffer [22]. Protein concentrations were determined by
standard technique. After SDS-PAGE separation, proteins
were transferred to nitrocellulose membranes and incubated
with specific antibodies for Akt, ERK1/2, Cx43. Specific HRP-
conjugated secondary antibodies were used according to the
manufacturer’s recommendations (Santa Cruz Biotechnology-
DBA Italia, MI, Italy). Specific protein bands were detected by
chemiluminescence using the Chemidoc XRS system (Bio-Rad
Laboratories, MI, Italy).
Statistical analysis
Data analysis was performed using analysis of variance
(ANOVA) with SPSS10.0 software (SAS Institute Inc., Cary,
NC, USA). When a significant overall effect was found,
Bonferroni test was used to compare mean values. Values of
p<0.05 were considered statistically significant.
Results
AT1R Blockade Improves LV performance and Inhibits
Detrimental Pathologic Molecular Adaptations by
Reducing LVH
Ascending aorta banding determined LVH after 12 weeks, as
indicated by morphometric measurements (28.6% increase in
left ventricular weight/body weight, LVW/BW; 32.7% increase
in heart weight/body weight, HW/BW, p<0.05 vs. all) and
echocardiographic parameters (26.1% increase in IVSWth;
25.9% increase in PWth, p<0.05 vs. all) when compared to
sham-operated animals. Chronic treatment with VAL
significantly reduced LVH (LVW/BW=1.92±0.12; HW/
BW=2.53±0.13; IVSWth=1.47±0.08; PWth=1.35±0.06, Table 1,
and Figure 1).
Hemodynamic studies, performed 12 weeks after banding,
demonstrated normal systemic pressure values (both systolic
and diastolic, Figure 2A and 2B) among the four groups; as
expected, aortic banding was associated to an increased LV
pressure (216.0±22.3 mmHg for LVH group; 178.8±13.2mmHg
for LVH+VAL group, compared to sham-operated animals
(p<0.01 vs. SHAM and SHAM+VAL, Figure 2C), whereas
LVEDP was found elevated only in the LVH group
(12.8±5.6mmHg, p<0.01 vs. all, Figure 2D). Furthermore,
contractile function was assessed by measuring the maximal
and minimal first derivative of the LV pressure over time
[LV(dP/dtmax) and LV(dP/dtmin), respectively, Figure 2E and 2F]
demonstrating increase in both systolic (dP/dtmax,
9432.9±2259.7 mmHg/s) and diastolic (dP/dtmin,
-7240.1±1591.3 mmHg/s) functions in LVH+VAL compared to
LVH and to sham-operated controls. Finally, trans-stenotic
systolic pressure gradient, calculated as difference between
supravalvular systolic pressure and systolic blood pressure,
Table 1. Morphometric and echocardiographic parameters
from sham-operated and pressure-overloaded rats treated
with Valsartan or placebo for 12 weeks after surgery.
 SHAM (N=10)
SHAM+VAL
(N=10) LVH (N=12)
LVH+VAL
(N=10)
BW, g 352.2 ± 8.7 350.3 ± 14.2 345.2 ± 18.2 351.6 ± 17.5
LVW, mg 639.4 ± 7.8 638.3 ± 12.8 817.5 ± 10.9* 667.4 ± 8.9
RVW, mg 138.6 ± 8.4 137.3 ± 8.2 152.8 ± 7.7* 130.6 ± 8.7
AW, mg 49.6 ± 5.3 53.0 ± 6.1 86.0 ± 9.3* 82.3 ± 8.9
HW, mg 827.6 ± 0.5 828.6 ± 0.8 1056.3 ± 0.12* 880.3 ± 0.13
LVW/BW,
mg/g 1.84 ± 0.02 1.85 ± 0.01 2.38 ± 0.09* 1.92 ± 0.12
HW/BW, mg/g 2.32 ± 0.05 2.31 ± 0.08 3.08 ± 0.11* 2.53 ± 0.13
LW, mg 1243.2 ± 59.7 1236.8 ± 64.0 1308.5 ± 55.0 1305.4 ± 49.6
LVEDD, mm 4.90 ± 0.28 4.87 ± 0.27 4.79 ± 0.37 4.94 ± 0.35
LVESD, mm 2.18 ± 0.10 2.22 ± 0.26 2.72 ± 0.26 2.50 ± 0.24
IVSWth, mm 1.40 ± 0.07 1.38 ± 0.06 1.74 ± 0.20* 1.47 ± 0.08
PWth, mm 1.39 ± 0.07 1.38 ± 0.13 1.75 ± 0.12* 1.35 ± 0.06
FS, % 55.5 ± 1.9 54.3 ± 4.3 43.2 ± 2.4* 49.5 ± 3.1
Values are expressed as mean ± SEM. SHAM, rats undergone left thoracotomy;
SHAM+VAL, rats undergone left thoracotomy followed by administration of
10mg/kg/die Valsartan; LVH, rats undergone left thoracotomy and aortic banding
with tantalum clip; LVH+VAL, rats undergone left thoracotomy and aortic banding
with tantalum clip followed by administration of 10mg/kg/die Valsartan; BW, body
weight; LVW, left ventricular weight; RVW, right ventricular weight; AW, left plus
right atria weight; HW, whole heart weight; LW, lungs weight; LVEDD, left
ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter;
IVSWth, interventricular septum wall thickness; PWth, posterior wall thickness; FS,
fractional shortening. Analysis of variance for unpaired data was used to analyze
results. *p<0,05 vs. all.
microRNA-1 and Ventricular Tachyarrhythmias
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was confirmed in rats subjected to ascending aorta banding
(LVH= 60.1±22.1mmHg; LVH+VAL= 53.4±24.6mmHg, p=NS),
indicating a superimposable stress to hearts of both banded
groups along the entire duration of the study.
Accumulating evidences strongly implicate AngII intracellular
signaling in mediating pathologic cardiac remodeling and
failure [6,30]. AngII activates various intracellular protein
kinases, and among them the serine/threonine kinases of the
mitogen-activated protein kinase (MAPK) family, and the Akt/
protein kinase B play a key role in mediating AngII/AT1R
effects. Thus, total and phosphorylated (activated) levels of
ERK1/2 and Akt were investigated in order to assess the
signaling pathways downstream AT1R. A three-fold increase in
p-ERK1/2 was observed in LVH group compared to SHAM
(1.6±0.3 vs. 0.5±0.7, p<0.05), and a similar increase was
detected in LVH+VAL vs. SHAM+VAL (2.4 fold increase,
1.3±0.3 vs. 0.5±0.2, p<0.05), with ~30% difference between
LVH and LVH+VAL (Figure 3A). On the other hand, aortic
banding determined a significant increase in phospho-Akt
levels twelve weeks after development of hypertrophy
compared to controls both in placebo groups (1.1±0.9 vs.
2.8±0.3, SHAM vs. LVH, p<0.01) and in valsartan groups
(1.7±1.1 vs. 4.4±0.6, SHAM+VAL vs. LVH+VAL, p<0.01).
Interestingly, valsartan treatment in aortic banded rats
produced a 54% increase in p-Akt when compared to the
untreated aortic banded hypertrophic group (p<0.05, Figure
3B). Therefore, a differential activation of ERK1/2 and Akt was
Figure 1.  Representative echocardiographic acquisitions from each group of rats.  Two-dimensional parasternal long axis
images demonstrating increase in wall thickness after ascending aorta banding (LVH) compared to control groups (SHAM, top left
panel; SHAM+VAL, top right panel) and reduction in the extent of hypertrophy after chronic valsartan administration (LVH+VAL).
Depth: 5mm, digital acquisition speed: 100mm/s.
doi: 10.1371/journal.pone.0070158.g001
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Figure 2.  Cumulative data on hemodynamic findings from sham-operated and pressure-overloaded rats.  A: Valsartan
administration improved systolic and diastolic (B) profiles (systolic blood pressure and diastolic blood pressure, SBP and DBP,
respectively) in hypertrophied rats. C: Banding of the ascending aorta determined a significant increase in left ventricular maximal
pressure (LV max), whereas LV end-diastolic pressure (LVeDP, panel D) was significantly higher in hypertrophic hearts compared
to both sham groups and Valsartan-treated hypertrophic hearts. E, F: The maximal and minimal first derivative of the LV pressure
over time [LV(dP/dtmax) and LV(dP/dtmin), respectively] demonstrated improved cardiac function in rats treated with Valsartan for
twelve weeks after aortic banding (*p<0.03 vs. all; # p<0.05 vs. SHAM and SHAM+VAL).
doi: 10.1371/journal.pone.0070158.g002
microRNA-1 and Ventricular Tachyarrhythmias
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observed upon banding in the LVH group compared to the LVH
+VAL group.
A sustained benefit from reducing the extent of hypertrophy
was observed over the entire range of chronic pressure
overload (20.1÷89.6mmHg, trans-stenotic systolic pressure
gradient) as it was plotted against the entire range of activated
Akt (14.4÷77.6 arbitrary unit, p-Akt area, Figure 3C) indicating
that the administration of the AT1R inhibitor in animals with
cardiac pressure overload induced a significant increase in
cardiac protective pro-survival signaling.
Left Ventricular Hypertrophy is associated with
increased susceptibility to ventricular
tachyarrhythmias
Basal electrocardiographic acquisitions in anesthetized rats
did not display any difference in HR among the groups (Table
2). Of note, an increased number of premature ventricular
contractions (PVC) was observed in LVH vs. SHAM group
(1200±180counts/hr vs. 255±165counts/hr, p<0.03 vs. all).
These PVCs were mostly characterized by R-on-T phenomena
and were detected before starting the electrophysiologic study.
Interestingly, the reduction in the extent of cardiac hypertrophy
by Valsartan was associated with a decrease in PVC counts
(LVH+VAL= 650±200counts/hr, p<0.05 vs. SHAM and SHAM
+VAL). The intracavitary stimulation performed after 12 weeks
did not trigger VT in sham-operated control rats (Figure 4A); on
the contrary, provocative invasive study displayed an increased
incidence of VT in hypertrophied rats compared to sham rats
(8/12, 66.7%, Figure 4B). The arrhythmic vulnerability,
represented by susceptibility to ventricular fibrillations and/or
sustained ventricular tachycardias at the end of
electrophysiologic study, was dramatically reduced in
hypertrophic rats treated with VAL (1/10, 10%, p<0.006, Figure
4C). In order to provide overall mechanistic effect of
arrhythmogenesis, spontaneous calcium transients were
assessed in cultured cardiomyocytes. In fact, it has been
recently reported that AngII enhances L-type calcium channel
current in cardiomyocytes during depolarization [31] and
thereby increases intracellular calcium loading, which may
result in triggered activity and arrhythmia. To this regard,
calcium transient monitoring demonstrated increased levels
upon AngII stimulation (2.4±0.4) compared to control cultured
cardiomyocytes (1.6±0.1, Figure 5A) which were reduced by
valsartan administration (Val= 1.5±0.1; AngII+Val= 2.0±0.2,
*p<0.05 vs. all, # p<0.003 vs. Con and AngII). Moreover, VERP
(Figure 5B) and MAPD90 (Figure 5C) were significantly reduced
in hypertrophic hearts, whereas valsartan treatment was
associated to restoration at basal values of both parameters.
Finally, the intracavitary electrophysiological study provided
additional data on conduction velocity, since QRS complexes
were significantly wider (Table 2, and Figure 5, D through G) in
LVH compared to LVH+VAL and to sham-operated rats.
Cx43 expression and phosphorylation is altered upon
hypertrophic stress in vitro and in vivo
Cx43 is phosphorylated at its C-terminus residues (S255/
S262/S279/S282) by MAPKs altering gap junction formation
[32]. This activation leads to a sharp modification of the pore-
channel function, resulting in a conformational change that
reduces the permeability and conductance of the channel. This
phenomenon implies an overall reduction in conduction velocity
and greater global dispersion of action potential and
refractoriness, maintaining an arrhythmogenic substrate [33].
In vivo Cx43 expression and its Ser 279/282-phosphorylation
were significantly increased in LVH group compared to sham-
operated rats (p<0.05 vs. all) whereas chronic VAL
administration in hypertrophied rats determined a significant
decrease of both total and phosphorylated Cx43 in cardiac
lysates (Figure 6A). Normalization of Ser 279/282-
phosphorylation to total Cx43 protein levels shows that this
post-translation modification was modulated by LVH on top of
the increased protein expression and thus VAL reduced both
Ser 279/282-phosphorylation and total Cx43 protein levels
(Figure 6A). Importantly, immunohistochemistry and confocal
microscopy revealed that Ser 279/282-phospho-Cx43 was
dispersed away from the intercalated disks of cardiomyocytes
in the LVH group. Accordingly, valsartan treatment reduced the
amount of phospho-Cx43 within cardiomyocyte cytoplasmic
compartments (Figure 6B).
Concurrently, immunoblotting analysis on cultured
cardiomyocytes revealed a 3-fold increase of Cx43 protein
expression associated with a marked Ser 279/282-
phosphorylation (>6 fold over control) upon challenge with
AngII 5µmol/L stimulation for three hours compared to control
cardiomyocytes (Figure 6C). Concomitant in vitro stimulation
with VAL (10µmol/L) significantly prevented AngII-induced
increase in Cx43 protein levels and its hyper-phosphorylation
(Figure 6C). AngII-induced Cx43 hyper-phosphorylation
determined a displacement of Cx43 from the gap junction as
demonstrated by a decreased amount of total Cx43 protein
levels in the myocyte membrane fraction when compared to
untreated normal myocytes. Intriguingly, Valsartan and the
MAPK/ERK1/2 kinase inhibitor (PD98059) both increased Cx43
expression within the myocyte membrane and consequently in
the gap junction in AngII-treated myocytes (Figure 6D).
miR-1 modulates Cx43 expression and phosphorylation
in hypertrophic cardiomyocytes
MiR-1 is abundantly expressed in skeletal and cardiac
muscle, and it directly targets Cx43 for repression [34,35]. To
investigate the relationship between electrical remodeling of
pressure-overloaded hypertrophic hearts and miR-1 levels, we
first assessed the differential expression of this miRNA in
SHAM, SHAM+VAL, LVH and LVH+VAL rats. MiR-1 was
significantly down-regulated in hypertrophic and arrhythmic
group of rats (LVH) in contrast to sham-operated rats (-61%
decrease, p<0.01 vs. all, Figure 7A, left panel). In hypertrophic
rats treated with VAL, the expression levels of miR-1 were
increased (115%) returning to the normal baseline values of
the sham-operated groups (-16% decrease, p=NS).
Furthermore, AngII stimulation significantly down-regulated
(-68% decrease) miR-1 levels in cultured myocytes vs. un-
stimulated cells (p<0.03 vs. all, N=6), whereas Valsartan
administration reduced miR-1 down-regulation by AngII
treatment in vitro (Figure 7A, right panel).
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Figure 3.  The maladaptive and detrimental molecular activation in hypertrophic hearts is attenuated by AT1R blockade.  A:
Increased phosphorylation of MAPK-ERK1/2 was observed in LVH group (1.6 fold over sham) compared to sham groups and to
LVH+VAL group (1.3 fold over sham, *p<0.05 vs. all). B: Cardiac levels of activated Akt were significantly higher twelve weeks after
aortic banding compared to sham-operated rats (2.8 fold over sham, # p<0.05 vs. SHAM and SHAM+VAL), and were even more
increased in hypertrophic group treated with valsartan (4.4 fold over sham, *p<0.05 vs. all). C: Correlation between trans-stenotic
systolic supravalvular gradient and activation of Akt in hypertrophied hearts; untreated rats with aortic banding (squares, LVH,
N=12) show reduced levels of p-Akt over the entire spectrum of systolic gradients (20.1÷89.6mmHg) compared to hypertrophied rats
treated with valsartan (circles, LVH+VAL, N=10).
doi: 10.1371/journal.pone.0070158.g003
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As above reported, Cx43 protein expression and
phosphorylation is increased in hypertrophic cardiomyocytes of
rats with aortic banding. Accordingly, we observed that Cx43
mRNA levels are also up-regulated in the LVH group (Figure
7B, left panel). Additionally, in vitro experiments showed an
almost three-fold increase of Cx43 mRNA levels by AngII when
compared to untreated cardiomyocytes (p<0.05, vs. all, N=6).
Valsartan significantly reduced AngII stimulated Cx43 mRNA
up-regulation in in vitro cardiomyocytes (Figure 7B, right
panel). Thus, Cx43 mRNA and protein levels are up-regulated
with a concurrent down-regulation of miR-1 levels in aortic
banded hearts in vivo as it is expected by miR-1 direct
targeting of Cx43 [32]. Indeed, we confirmed through gain
(using a miR-1 mimic) and loss (Anti-miR-1) of function in vitro
experiments that miR-1 directly modulates Cx43 levels (Figure
7C).
Finally, we tested whether miR-1 plays a direct role in the
modulation of Cx43 activity in an in vivo hypertrophic heart. To
this aim, either an Ad-miR-1 or an Ad-Empty intra-myocardial
deliver was performed in C57BL/6 mice and 72 hrs later the
adenoviral-infected mice were treated with Isoproterenol (Iso)
to induce LVH or just saline as control (Con) for 14 days. At
sacrifice, miR-1 was correctly over-expressed in Ad-miR-1
treated mice when compared to Ad-Empty (Figure 8A). Iso
induced significant reactive cardiomyocyte hypertrophy (cross
sectional area, 306±18µm2 vs. 222±11µm2 in Con; p<0.05) and
miR-1 down-regulation in Ad-Empty mice (Figure 8A). On the
other hand, Ad-miR-1 overexpression prevented cardiomyocyte
hypertrophic response to Iso treatment (cross sectional area,
233±12µm2; p=NS vs. Con and p<0.05 vs. Iso). Importantly, in
agreement with the data on rat LV hypertrophy by aortic
banding, miR-1 down-regulation by Iso-mediated hypertrophy
was associated with Cx43 increased protein levels and
enhanced phosphorylation (Figure 8B). The increased
phosphorylation of Cx43 correlated with its displacement from
Table 2. Surface electrocardiographic parameters,
intracavitary electrograms recordings, and
electrophysiological properties of endocardial cells in sham-
operated and in pressure-overloaded rats treated with
Valsartan or placebo for 12 weeks after surgery.
 SHAM (N=10)
SHAM+VAL
(N=10) LVH (N=12)
LVH+VAL
(N=10)
HR, bpm 437±38 434±49 399±61 392±49
RR interval, ms 138±11 140±16 155±33 155±19
PVC, counts/hr 255±165 360±162 1200±180* 650±200#
QRS duration, ms 11.2±0.8 11.4±1.0 15.1±1.3* 12.0±0.8
QRS amplitude, mV 2.0±0.1 2.0±0.2 3.2±0.3* 2.8±0.2#
Values are expressed as average ± SEM. SHAM, rats undergone left lateral
thoracotomy only; SHAM+VAL, rats undergone left lateral thoracotomy and treated
with valsartan 10 mg/kg/die; LVH, rats undergone aortic banding; LVH+VAL, rats
undergone aortic banding and treated with valsartan 10 mg/kg/die; HR, heart rate;
bpm, beats per minute; RR interval, length between two consecutive ventricular
depolarizations; PVC, premature ventricular contractions; ms, milliseconds; mV,
milliVolts. Analysis of variance has been used in data analysis. *p<0,05 vs. all;
#p<0,05 vs. SHAM and SHAM+VAL.
the gap junction (Figure 8C). Importantly, miR-1
overexpression significantly reduced Cx43 protein levels with a
concomitant significant reduction of its phosphorylated levels
(Figure 8B). Accordingly, the gap-junction displaced and
myocyte cytoplasmic accumulated hyper-phosphorylated Cx43
in hypertrophic hearts was significantly reduced in the Ad-
miR-1 treated mice (Figure 8C). Thus, these data above
provide the first direct evidence that miR-1 plays a major role in
the modulation of Cx43 activity and location in in vivo cardiac
hypertrophy.
Overall these data indicate that a hypertrophic stimulus on
cardiomyocytes induces miR-1 down-regulation increasing the
expression of Cx43, which in turn is phosphorylated by the
hypertrophic stress-induced MAP kinases and so drifted away
from the gap junction. The latter phenomenon leads to the
increased susceptibility to develop life-threatening VT in the
hypertrophic hearts. Intriguingly, an anti-hypertrophic agent,
such as the AT1R blocker Valsartan, appears to exert its
beneficial effects at least in part by attenuating this detrimental
molecular pathway activation.
Discussion
The main findings of this study document that: i) connexin 43
expression and activity (with its consequent displacement from
the gap junction) increases in response to hypertrophic stress
in cardiomyocytes in vitro and in vivo; ii) miR-1 directly targets
for Cx43 repression and it is concurrently down-regulated in
hypertrophic cardiomyocytes in vitro and in vivo; iii) molecular
myocyte remodeling in cardiac hypertrophy increases MAPK-
ERK1/2 activation, which in turn hyper-phosphorylated Cx43
and this shift redistributes Cx43 away from the intercalated
disks favoring gap junction disassembling; iv) the hypertrophic
myocardium is therefore prone to ventricular tachyarrhythmia
(VT); v) angiotensin II type 1 receptor (AT1R) blockade
reduces the maladaptive hypertrophic signaling inhibiting
ERK1/2 activation while maintaining the pro-survival Akt
function, attenuating miR-1 down-regulation and Cx43
displacement from the gap junction. The latter appears to be
one of the molecular mechanisms modulated by AT1R
blockade to reduce the life-threatening hypertrophic-dependent
VT.
Cardiac hypertrophy is an independent risk factor for the
development of arrhythmias, diastolic dysfunction, congestive
heart failure and death, as assessed in experimental models
and in humans [3,35–38]. The occurrence of malignant VT is
determined by increased automaticity, enhanced heterogeneity
of conduction, neuro-humoral changes, structural remodeling
and alterations in expression and distribution of gap-junctions
and ion channels [39,40]. In the mammalian heart, a connexin
composed of 342 amino acid residues with a molecular weight
of 43000 (Cx43) is the most abundant connexin. Hypertrophied
rats have changes in quantity and subcellular localization of
Cx43 [41]. In particular, the cell-to-cell electrical uncoupling of
cardiomyocytes plays an important role in determining
ventricular arrhythmogenesis during hypertrophy [5,37,42]. In
this study we have shown that cardiac hypertrophy is
characterized by an aberrant increased expression of Cx43,
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Figure 4.  Susceptibility to the onset of ventricular tachyarrhythmias assessed during programmed electrical
stimulation.  A: Programmed electrical stimulation (PES) was performed with a dedicated bipolar catheter, which was advanced
anterogradely into the right ventricle. A train of N=20 impulses at 100ms of basal cycle length followed by three extrastimuli at 50ms
was used in each case; no arrhythmias were inducible in rats from neither SHAM nor SHAM+ VAL groups. B: R-on-T phenomena
before and after stimulation in hypertrophied rat hearts with the induction of a sustained ventricular tachycardia at the end of
stimulation. C: In contrast, after valsartan administration only ventricular extra beats were inducible in hypertrophied rats in which
stable sinus rhythm was restored at the end of stimulation. Central strips from each panel start from previously recorded 1000ms of
respective upper strips, as for bottom strips from panels A and C, whereas bottom strip from panel B is postponed of 24 seconds
due to induction of sustained ventricular tachycardia.
doi: 10.1371/journal.pone.0070158.g004
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Figure 5.  Valsartan modulation of electrophysiological properties in vitro and in vivo.  A: Bar graph demonstrating average
peak systolic amplitude of the calcium transients, expressed as absolute numbers from ratio between the peak of fluorescence
intensity (F) and the intensity at rest (F0): AngII stimulation (10-6mol/L; 24 hours) augmented transients in cultured myocytes, which
were attenuated by the AngII type 1 receptor blocker valsartan. Valsartan alone did not change the amplitude of calcium transient.
The mean peak F/F0 was significantly higher in AngII–treated cells than control cells (*p<0.05 vs. all, # p<0.003 vs. Con and AngII).
B: Ventricular effective refractory period (VERP) was dramatically reduced in LVH (37.3±3.4ms) compared to SHAM (52.3±2.6ms),
SHAM+VAL (55.1±3.3ms), and LVH+VAL (51.9±2.9ms, *p<0.001 vs. all). C: Monophasic action potential duration at 90%
repolarization (MAPD90) was significantly shortened in hypertrophic hearts (LVH= 44.0±4.3ms) as opposed to control groups
(SHAM= 56.7±2.9ms; SHAM+VAL= 59.1±2.5ms), whereas valsartan significantly prolonged it (LVH+VAL= 55.6±4.3ms *p<0.001 vs.
all). D through G: Representative endocardial ventriculograms recorded from the right ventricles indicating normal myocardial
conduction in SHAM (panel D) and in SHAM+VAL (panel E), whereas conduction dispersion was observed in LVH (panel F) and
LVH-VAL (panel G), the latter showing same duration in ventricular activation compared to SHAM and SHAM+VAL. Arrows indicate
onset of ventricular depolarization, arrow-heads indicate end of ventricular depolarization, followed by abnormal repolarization in
hypertrophic hearts, which was more pronounced in LVH (panel F, see Table 2 for data).
doi: 10.1371/journal.pone.0070158.g005
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Figure 6.  Phosphorylation at residues Ser279/Ser282 is associated with connexin 43 displacement.  In vivo (A) and in vitro
(C) phosphorylated levels of Connexin 43. A: An increased Cx43 total protein expression along with its hyperphosphorylation at
Ser279/Ser282 was observed in cardiac lysates from hypertrophic hearts compared to SHAM and SHAM+VAL, while chronic
administration of Valsartan reduced both these two molecular responses; *p<0.05 vs. Sham; #p<0.05 vs. LVH. B: high-magnification
immunohistochemistry and confocal representative images (red: α-sarcomeric actin, α-SA; green: Cx43 or p-Cx43; blue: DAPI)
show normal Cx43 localization within gap-junction (panel a) and the very little, if not negligible, levels of Ser279/Ser282-
phosphorylated Cx43 (panel b) in rat SHAM hearts. LVH by pressure overload is associated with an intense Cx43 phosphorylation
at Ser279/282 and its displacement from gap junction (panel c). The latter is significantly attenuated by VAL treatment (panel d). C:
Increased protein levels and hyper-phosphorylation of Connexin 43 in cardiomyocytes treated with Angiotensin II (AngII, 5µmol/L)
compared to un-stimulated cardiomyocytes, with a significant reduction after concurrent valsartan administration (10µmol/L, *p<0.05
vs. Con; #p<0.05 vs. AngII). D: Representative western blot of Cx43 total protein levels in lysates from membrane fractions of
cultured cardiomyocytes. After AngII challenge, Cx43 was displaced from the gap junction as demonstrated by its reduced levels in
the membrane fractions (lane 2) compared to un-stimulated cells, whereas Valsartan (lane 3) and the MAPK/ERK1/2 kinase
inhibitor PD98059 (lane 4) both reduced Cx43 gap junction displacement in AngII-treated myocytes.
doi: 10.1371/journal.pone.0070158.g006
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Figure 7.  Molecular determinants of ventricular tachyarrhythmias in cardiac hypertrophy.  Real time RT-PCR for miR-1 (A)
and for Connexin 43 (B) levels. A: left panel, chronic pressure overload was associated with reduced miR-1 levels and increased
transcript levels of Cx43 (showed in panel B, left panel) compared to SHAM and SHAM+VAL; in contrast, valsartan administration
for twelve weeks after banding determined a restoration of miR-1 levels and reduced Cx43 levels almost to basal values (*p<0.05
vs. all, # p<0.05 vs. SHAM and SHAM+VAL). Right panel: cardiomyocytes stimulated with Angiotensin II showed lower expression
levels of miR-1 compared to unstimulated cardiomyocytes (Con), with increased miR-1 levels in AngII+Val group (*p<0.03 vs. all,
N=6); B, right panel: conversely, AngII challenge was associated with increased expression levels of Cx43, whereas valsartan
reverted this phenomenon (*p<0.05 vs. all, N=6). C: cultured cardiomyocytes provided additional evidences, through gain- and loss-
of-function assays, that Cx43 is a direct target of miR-1; cardiomyocytes were grown on 6-well plates to 70% confluence. Specific
miR-1 mimic (30nM per well), and Anti-miR-1 (60nM per well) were transfected using siPORT NeoFX Transfection Agent (Ambion)
according to the manufacturer’s protocol.
doi: 10.1371/journal.pone.0070158.g007
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Figure 8.  miR-1 modulates Cx43 activity in cardiac hypertrophy.  A: cardiac levels of miR-1 after adenovirus-mediated cardiac
overexpression in control saline-injected (Saline-Con) and in Iso-induced hypertrophic mice (Iso-LVH, *p<0.05 vs. Ad-Empty;
#p<0.05 vs. Saline-Con). B: total and phosphorylated (Ser279/Ser282) Cx43 levels in normal and hypertrophic mouse hearts after
Adeno-Empty or Adeno-miR-1 myocardial release (*p<0.05 vs. Ad-Empty; #p<0.05 vs. Saline-Con). C: immunohistochemistry and
confocal microscopy in murine normal and hypertrophic heart sections; panels a-b show normal Cx43 expression in the gap junction
(a) and very low level of its phosphorylation at Ser279/Ser282; ISO-induced LVH determined hyper-phosphorylation of Cx43 and its
displacement from the gap junction to the cytoplasm of hypertrophic cardiomyocytes (c); panel d shows a significant reduction of
phospho-Cx43 and its stabilization within the gap junction by adenovirus-mediated miR-1 selective intra-myocardial overexpression
(red: α-sarcomeric actin, α-SA; green: Cx43 or p-Cx43; blue: DAPI).
doi: 10.1371/journal.pone.0070158.g008
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whose increased levels have been already reported in different
experimental models in association with an abnormal
subcellular localization. In fact, Cx43 is located in physiological
conditions at the intercalated disks and lateralizes aberrantly
toward the Z lines, or it is internalized in endosomes inside the
cytoplasm in different pathologic conditions. Phosphorylation of
Cx43 has been implicated in the regulation of gap junction
communication at several stages of the connexin 'life cycle',
including hemichannel oligomerization, export of the protein to
the plasma membrane, hemichannel activity, gap junction
assembly, gap junction channel gating and connexin
degradation [32]. Cx43 phosphorylation is dynamic and
changes in response to activation of many different kinases,
including PKA (protein kinase A), PKC (protein kinase C),
p34cdc2 (p34cdc2/cyclin B kinase), protein kinase CK1, MAPK
(mitogen-activated protein kinase) and Src (pp60Src kinase)
[33]. Treatment of cells with different growth factors is
accompanied by increased Cx43 phosphorylation of serine
residues with the net effect typically being a reduction in gap
junction communication [43,44]. In particular, extracellular
mitogen stimulation can also lead to increased phosphorylation
of Ser255 and Ser279/Ser282, sites known to be MAPK family
substrates [43]. Phosphorylation of Ser279/Ser282 is important
in curtailment of gap junction communication, as these events
are able to decrease gap junction channel ‘open time’ [44].
Additionally, the Src tyrosine kinase, an upstream regulator of
MAPK activity, can also phosphorylate Cx43, and it negatively
affects Cx43 activity by multiple mechanisms [45]. The renin-
angiotensin system has been classically shown to be a major
regulator of pathologic cardiac hypertrophy [6]. Indeed,
Angiotensin II (AngII) is rapidly released from myocardial cells
in response to cardiac damage and stretch; after binding to the
AT1R, through Src, Ras, Gq and PKC mediation, it activates
the maladaptive extracellular signal-regulated protein kinase
1/2 (ERK1/2) generating pathological cellular growth
[20,30,46–49]. Valsartan, a classic non-competitive antagonist
of the AT1R, has been widely used in the clinical setting for the
treatment of patients with systemic hypertension and
concentric cardiac hypertrophy [50]. However, its role in
preventing VT that predispose to the risk of sudden cardiac
death still remains to be elucidated. In the present study,
valsartan administration significantly reduced the magnitude of
cardiac hypertrophy and the incidence of arrhythmias, both as
isolated ventricular ectopic beats in basal conditions and in the
form of organized VT elicited after invasive provocative study,
in rats after 12 weeks of pressure overload. In particular, AT1R
blockade was able to reduce both ERK1/2 phosphorylation and
ensuing Cx43 phosphorylation in vitro and in vivo, resulting in
normalization of gap junction communications. Thus, these
data lend support to a phenomenon whereby pressure
overload-dependent release of mitogen stimuli like AngII
activates ERK 1/2 that phosphorylates Cx43 reducing gap
junction communication. This detrimental signaling mediates
pathologic cardiac growth with the consequence of increasing
malignant arrhythmias development.
Cx43 has been already established as a target of miR-1 [34].
The latter is dramatically reduced in cardiac hypertrophy, and
contributes significantly to the overexpression of Cx43, hence
determining part of the arrhythmogenic substrate of cardiac
hypertrophy, whereas other receptors might be involved in
maintaining other abnormal electrophysiological substrates
[40]. Moreover, cardiac miR-1 levels have been found reduced
in pathological conditions such as acromegaly [51]. Here we
confirm these data and provide the first evidence that AT1R
blockade prevents miR-1 down-regulation in hypertrophic
stressed cardiomyocytes. Intriguingly, MAPKs are known
regulators of miR-1/miR-133 biogenesis [52] and we have
recently shown in vascular smooth muscle cell that ERK1/2
activation suppresses miR-133 expression [13], the miR-1
cognate bicistronic gene. Thus, it is tempting to speculate that
ERK1/2 dependent signaling stimulated by cardiac stretch and
AngII release mediates miR-1 down-regulation and Cx43
increased expression. The latter, as shown in the present
study, is then hyper-phosphorylated by ERK1/2, decreasing
gap junction communications, which may explain the increased
risk of malignant VT in cardiac hypertrophy. Furthermore,
miR-1 overexpression inhibits MAPK-ERK1/2 phosphorylation
in hypertrophic cardiomyocytes in vivo [53]. The latter
molecular adaptation provides a potential explanation of our
findings showing that miR-1 regulates not only Cx43
expression through the expected gene silencing mechanism
but it also indirectly modulates Cx43 activity. Indeed, we
speculate that miR-1 overexpression leads to inhibition of ERK
1/2 phosphorylation in vivo, and the latter in turn prevents Cx43
phosphorylation and displacement from the gap junction.
Nevertheless, further studies are still needed to prove this
hypothesis.
Finally, in the present study we show that Valsartan-
dependent reduction of cardiac hypertrophy induced by aortic
constriction is associated with increased activated Akt levels
(with a parallel reduction in ERK1/2 phosphorylation) when
compared to rats with the sole aortic banding. While the latter
is surprising considering the known role of Akt in
cardiomyocyte growth [54], this finding generates the
hypothesis that Akt activation in absence of concurrent ERK1/2
activation leads to an attenuated and beneficial adaptive
cardiac response to pressure overload that improves cardiac
function. Incidentally, Akt activation is indeed responsible for
physiological cardiac growth by exercise training that is
followed by an improved performance [55]. This beneficial
adaptive activation of Akt in physiological hypertrophy as
opposed to the detrimental signaling pathways (including the
MAPKs) underlying pathological cardiac growth is the basis for
these two different types of cardiac hypertrophy. It is also
intriguing to speculate that Akt activation in absence of MAPK
activity triggers a pro-endothelial secretory response in
myocytes that increases capillarization during cardiac growth
[56]. Nevertheless, it remains unanswered whether Akt has a
role in modulating VT.
In conclusion, this study provides in vivo and in vitro
evidences that the selective AT1R inhibition reduces total and
phosphorylated levels of Cx43 through miR-1 expression
normalization and ERK1/2 inhibition in hypertrophic stressed
cardiomyocytes. Accordingly, the development of LVH,
occurrence of hyperkinetic VT and reduction in cardiac function
after pressure overload in an experimental rat model of
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ascending aortic banding are prevented by AT1R which is
associated with the attenuation of miR-1 down-regulation and
the consequent stabilization of Cx43 activity within the gap
junction. These data increase knowledge on the signaling
pathways responsible for LVH and the related mechanisms of
VT, opening new avenues to the modulation of microRNAs as
potential therapeutic targets in this clinical setting.
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